Brain cell membrane motion-restricted phospholipids in patients with schizophrenia who have seriously and dangerously violently offended

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 3, 2008, Pages 751-754

  Puri, Basant K ^a   Counsell, Serena J ^a   Hamilton, Gavin ^a   Bustos, Marcelo G ^b   Treasaden, Ian H ^b  

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

^b WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

Author keywords

Brain phospholipids; Schizophrenia; Spectroscopy

Indexed keywords

MEMBRANE PHOSPHOLIPID; PHOSPHATASE; PHOSPHODIESTERASE;

ADULT; ARTICLE; BRAIN CELL; CELL MEMBRANE; CELL MOTION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IN VIVO STUDY; MALE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; VIOLENCE;

ADULT; BRAIN; CASE-CONTROL STUDIES; CELL MEMBRANE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHOLIPIDS; PHOSPHORUS ISOTOPES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VIOLENCE;

EID: 40049112138     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.11.025     Document Type: Article

References (25)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1992), American Psychiatric Association, Washington, DC
2. Atkins M., Burgess A., Bottomley C., and Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr Bull R Coll Psychiatr 21 (1997) 224-226
3. Bates C., Horrobin D.F., and Ellis K. Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant for schizophrenia. Schizophr Resfs 6 (1991) 1-7
4. 31P NMR detection of mobile dog brain phospholipids. Magn Reson Med 3 (1986) 432-436
5. Foster P., and Neuroleptic equivalence. Pharm J 243 (1989) 431-432
6. Gattaz W.F., Hubner C.V., Nevalainen T.J., Thuren T., and Kinnunen P.K. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatry 28 (1990) 495-501
7. Gattaz W.F., Kollisch M., Thuren T., Virtanen J.A., and Kinnunen P.K. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry 22 (1987) 421-426
8. Gattaz W.F., Schmitt A., and Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res 16 (1995) 1-6
9. Glen A.I., Glen E.M., Horrobin D.F., Vaddadi K.S., Spellman M., Morse-Fisher N., et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 12 (1994) 53-61
10. Hamilton G., Mathur R., Allsop J.M., Forton D.M., Dhanjal N.S., Shaw R.J., et al. Changes in brain intracellular pH and membrane phospholipids on oxygen therapy in hypoxic patients with chronic obstructive pulmonary disease. Metab Brain Dis 18 (2003) 95-109
11. 31P MR spectra. NMR Biomed 16 (2003) 168-176
12. Horrobin D.F. Phospholipid and fatty acid biochemistry in schizophrenia. In: Peet M., Glen I., and Horrobin D.F. (Eds). Phospholipid spectrum disorders in psychiatry and neurology. 2nd ed. (2003), Marius Press, Carnforth 123-162
13. Horrobin D.F., Glen A.I., and Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 13 (1994) 195-207
14. Horrobin D.F., Manku M.S., Hillman H., and Glen I.A.M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 30 (1991) 795-805
15. Horrobin D.F., Manku M.S., Morse-Fisher N., Vaddadi K.S., Courtney P., Glen A.I., et al. Essential fatty acids in plasma phospholipids in schizophrenics. Biol Psychiatry 25 (1989) 562-568
16. Kaiya H., Horrobin D.F., Manku M.S., and Fisher N.M. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biol Psychiatry 30 (1991) 357-362
17. 31P NMR spectroscopic study. Magn Reson Med 6 (1988) 296-299
18. Naressi A., Couturier C., Devos J.M., Janssen M., Mangeat C., de Beer R., et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 12 (2001) 141-152
19. Ohara K. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 469-474
20. Peet M., Laugharne J., Rangarajan N., Horrobin D., and Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 29 (1995) 227-232
21. Puri B.K., Counsell S.J., Hamilton G., Bustos M.G., Horrobin D.F., Richardson A.J., et al. Cerebral metabolism in male patients with schizophrenia who have seriously and dangerously violently offended. Prostaglandins Leukot Essent Fatty Acids 70 (2004) 409-411
22. Saeed N., and Menon D.K. A knowledge-based approach to minimize baseline roll in chemical shift imaging. Magn Reson Med 29 (1993) 591-598
23. Vanhamme L., Van Den Boogaart A., and Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129 (1997) 35-43
24. Yao J.K., Van Kammen D.P., and Gurklis J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr Res 13 (1994) 227-232
25. Yao J.K., Van Kammen D.P., and Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 13 (1994) 217-226